The Health Service Executive could face a loss of up to €7m due to its dealings with a medical devices company that provided respiratory technology during the Covid-19 pandemic.
The Public Accounts Committee (PAC) was told that the HSE bought respiratory products from the company, spending around €15m between 2020 and 2024.
However, the purchases were not compliant with its procurement process. The company in question later went into liquidation, meaning there was "no hope" of the HSE recovering losses of between €5m and €7m, Chief Executive Bernard Gloster told PAC.
The HSE did not carry out adequate checks on the stock received from the company, while on one occasion it made a double payment of €723,000 on the same invoice, he said.
Read more on rte.ie